Anhui Anke BioTech Group Total Assets
Anhui Anke BioTech Group total assets. Based on the latest financial reports, Anhui Anke BioTech Group (300009) holds total assets worth CN¥5.13 Billion CNY (≈ $750.12 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Anhui Anke BioTech Group for the company's overall valuation and market capitalisation.
Total Assets of Anhui Anke BioTech Group (2006–2025)
Total assets of Anhui Anke BioTech Group from 2006 to 2025. This chart illustrates how Anhui Anke BioTech Group's total assets have evolved over time, based on quarterly financial data. See Anhui Anke BioTech Group stock price for real-time trading data and today's change.
Anhui Anke BioTech Group - Asset Composition Analysis
Anhui Anke BioTech Group Total Assets Breakdown (December 2025)
Anhui Anke BioTech Group total assets breakdown as of December 2025. Anhui Anke BioTech Group's total assets of CN¥5.13 Billion consist of 43.2% current assets and 56.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.5% |
| Accounts Receivable | CN¥407.94 Million | 7.4% |
| Inventory | CN¥252.75 Million | 4.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥592.53 Million | 10.7% |
| Goodwill | CN¥66.56 Million | 1.2% |
Asset Composition Trend (2006–2025)
This chart illustrates how Anhui Anke BioTech Group's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Anhui Anke BioTech Group short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anhui Anke BioTech Group's current assets represent 43.2% of total assets in 2025, an increase from 38.5% in 2006.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2025, down from 14.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 8.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 10.7% of total assets.
Anhui Anke BioTech Group Competitors by Total Assets
Key competitors of Anhui Anke BioTech Group based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Anhui Anke BioTech Group - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.03 | 3.36 | 3.66 |
| Quick Ratio | 3.51 | 2.90 | 3.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.68 Billion | CN¥1.46 Billion | CN¥1.28 Billion |
Anhui Anke BioTech Group - Advanced Valuation Insights
This section examines the relationship between Anhui Anke BioTech Group's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.19 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | CN¥5.55 Billion |
| Market Capitalization | $1.97 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Anhui Anke BioTech Group's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Anhui Anke BioTech Group's assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Anhui Anke BioTech Group (2006–2025)
The table below shows the annual total assets of Anhui Anke BioTech Group from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.55 Billion ≈ $811.80 Million |
+8.03% |
| 2024-12-31 | CN¥5.14 Billion ≈ $751.46 Million |
+3.73% |
| 2023-12-31 | CN¥4.95 Billion ≈ $724.45 Million |
+16.30% |
| 2022-12-31 | CN¥4.26 Billion ≈ $622.91 Million |
+16.02% |
| 2021-12-31 | CN¥3.67 Billion ≈ $536.90 Million |
+3.97% |
| 2020-12-31 | CN¥3.53 Billion ≈ $516.39 Million |
+9.38% |
| 2019-12-31 | CN¥3.23 Billion ≈ $472.10 Million |
+27.67% |
| 2018-12-31 | CN¥2.53 Billion ≈ $369.77 Million |
+12.10% |
| 2017-12-31 | CN¥2.25 Billion ≈ $329.85 Million |
+14.70% |
| 2016-12-31 | CN¥1.97 Billion ≈ $287.58 Million |
+41.29% |
| 2015-12-31 | CN¥1.39 Billion ≈ $203.54 Million |
+51.92% |
| 2014-12-31 | CN¥915.58 Million ≈ $133.98 Million |
+22.11% |
| 2013-12-31 | CN¥749.81 Million ≈ $109.72 Million |
+14.84% |
| 2012-12-31 | CN¥652.93 Million ≈ $95.54 Million |
+8.16% |
| 2011-12-31 | CN¥603.65 Million ≈ $88.33 Million |
+2.39% |
| 2010-12-31 | CN¥589.55 Million ≈ $86.27 Million |
+8.70% |
| 2009-12-31 | CN¥542.36 Million ≈ $79.36 Million |
+143.25% |
| 2008-12-31 | CN¥222.96 Million ≈ $32.63 Million |
-5.75% |
| 2007-12-31 | CN¥236.55 Million ≈ $34.62 Million |
+4.80% |
| 2006-12-31 | CN¥225.72 Million ≈ $33.03 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more